BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33800561)

  • 1. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
    Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
    Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
    Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
    Front Immunol; 2020; 11():1008. PubMed ID: 32528479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
    Wang Z; Weiner GJ
    J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
    Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
    Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
    Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b.
    El Fatimy R; Subramanian S; Uhlmann EJ; Krichevsky AM
    Mol Ther; 2017 Feb; 25(2):368-378. PubMed ID: 28153089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
    Huang RS; Lai MC; Lin S
    Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer.
    Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
    J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Tim‑3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer.
    Wang Y; Sun J; Gao W; Song B; Shao Q; Zhao L; Zhang Y; Wang Q; Zhang Y; Qu X
    Mol Med Rep; 2017 Jun; 15(6):3810-3818. PubMed ID: 28440449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
    Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
    Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
    Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
    Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
    Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-Mediated Gene Knockout and Knockin Human iPSCs.
    Petazzi P; Menéndez P; Sevilla A
    Methods Mol Biol; 2022; 2454():559-574. PubMed ID: 33190185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of
    Shi Y; Abidan A; Li D; Zibigu R; Wang M; Zheng X; Kang X; Wang H; Li J; Zhang C
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2023 Sep; 35(4):366-373. PubMed ID: 37926471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.